These results suggest that BRAF-mutant PTC may have a specific tumor microenvironment that alters a patient’s prognosis and response to immunotherapy, which may also affect cell–cell communication that is relevant to our study, and provides us with clues for personalized diagnosis and treatment of PTC according to LR pairs. The gene discussed is BRAF; the disease is neoplasm.